{"id":802373,"date":"2025-01-21T02:33:04","date_gmt":"2025-01-21T07:33:04","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/nanobiotix-announces-first-patient-dosed-in-a-new-randomized-phase-2-study-evaluating-jnj-1900-nbtxr3-for-patients-with-stage-3-unresectable-non-small-cell-lung-cancer\/"},"modified":"2025-01-21T02:33:04","modified_gmt":"2025-01-21T07:33:04","slug":"nanobiotix-announces-first-patient-dosed-in-a-new-randomized-phase-2-study-evaluating-jnj-1900-nbtxr3-for-patients-with-stage-3-unresectable-non-small-cell-lung-cancer","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/nanobiotix-announces-first-patient-dosed-in-a-new-randomized-phase-2-study-evaluating-jnj-1900-nbtxr3-for-patients-with-stage-3-unresectable-non-small-cell-lung-cancer\/","title":{"rendered":"NANOBIOTIX Announces First Patient Dosed in a New Randomized Phase 2 Study Evaluating JNJ-1900 (NBTXR3) for Patients With Stage 3 Unresectable Non-Small Cell Lung Cancer"},"content":{"rendered":"
\n

PARIS and CAMBRIDGE, Mass., Jan. 21, 2025 (GLOBE NEWSWIRE) — NANOBIOTIX<\/a> (Euronext: NANO \u2013\u2013 NASDAQ: NBTX \u2013 the \u2018\u2018Company<\/strong>\u2019\u2019), a late-clinical stage biotechnology company pioneering nanoparticle-based therapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced that the first patient has been dosed in the CONVERGE study, a Phase 2 randomized controlled clinical trial evaluating potential first-in-class radioenhancer JNJ-1900 (NBTXR3) for the treatment of patients with Stage 3 unresectable non-small cell lung cancer receiving standard of care chemoradiation followed by consolidation durvalumab (NCT06667908<\/a>). CONVERGE is sponsored by Janssen Pharmaceutica NV, a Johnson & Johnson Company, under a global license agreement.<\/p>\n

\u201cWe believe the true value of JNJ-1900 (NBTXR3) is driven by its potential to address the unmet needs of the millions of patients each year who receive radiotherapy as part of their treatment,\u201d said Laurent Levy, Nanobiotix Chief Executive Officer and Chairman of the Executive Board. \u201cWith a clear path to potential registration in head and neck cancer established through NANORAY-312, the first patient dosed in the CONVERGE study in non-small cell lung cancer brings us another step closer to delivering for the large number of patients JNJ-1900 (NBTXR3) is designed to serve.\u201d<\/p>\n

\n About NBTXR3 (JNJ-1900)<\/strong>\n <\/p>\n

NBTXR3 is a novel, potentially first-in-class oncology product composed of functionalized hafnium oxide nanoparticles that is administered via one-time intratumoral injection and activated by radiotherapy. Its proof-of-concept was achieved in soft tissue sarcomas for which the product received a European CE mark in 2019. The product candidate\u2019s physical mechanism of action (MoA) is designed to induce significant tumor cell death in the injected tumor when activated by radiotherapy, subsequently triggering adaptive immune response and long-term anti-cancer memory. Given the physical MoA, Nanobiotix believes that NBTXR3 could be scalable across any solid tumor that can be treated with radiotherapy and across any therapeutic combination, particularly immune checkpoint inhibitors.<\/p>\n

Radiotherapy-activated NBTXR3 is being evaluated across multiple solid tumor indications as a single agent or in combination with anti-PD-1 immune checkpoint inhibitors, including in NANORAY-312\u2014a global, randomized Phase 3 study in locally advanced head and neck squamous cell cancers. In February 2020, the United States Food and Drug Administration granted regulatory Fast Track designation for the investigation of NBTXR3 activated by radiation therapy, with or without cetuximab, for the treatment of patients with locally advanced HNSCC who are not eligible for platinum-based chemotherapy\u2014the same population being evaluated in the Phase 3 study.<\/p>\n

Given the Company\u2019s focus areas, and balanced against the scalable potential of NBTXR3, Nanobiotix has engaged in a collaboration strategy to expand development of the product candidate in parallel with its priority development pathways. Pursuant to this strategy, in 2019 Nanobiotix entered into a broad, comprehensive clinical research collaboration with The University of Texas MD Anderson Cancer Center to sponsor several Phase 1 and Phase 2 studies evaluating NBTXR3 across tumor types and therapeutic combinations. In 2023, Nanobiotix announced a license agreement for the global co-development and commercialization of NBTXR3 with Janssen Pharmaceutica NV, a Johnson & Johnson Company.<\/p>\n

\n About NANOBIOTIX<\/strong>\n <\/p>\n

Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The Company\u2019s philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life.<\/p>\n

Incorporated in 2003, Nanobiotix is headquartered in Paris, France and is listed on Euronext Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020. The Company has subsidiaries in Cambridge, Massachusetts (United States) amongst other locations.<\/p>\n

Nanobiotix is the owner of more than 25 umbrella patents associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system.<\/p>\n

For more information about Nanobiotix, visit us at www.nanobiotix.com<\/a> or follow us on LinkedIn<\/a> and Twitter<\/a><\/p>\n

\n Disclaimer<\/strong>\n <\/p>\n

\n This press release contains \u201cforward-looking\u201d statements within the meaning of the \u201csafe harbor\u201d provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the use of proceed therefrom, and the period of time through which the Company\u2019s anticipates its financial resources will be adequate to support operations. Words such as \u201cexpects\u201d, \u201cintends\u201d, \u201ccan\u201d, \u201ccould\u201d, \u201cmay\u201d, \u201cmight\u201d, \u201cplan\u201d, \u201cpotential\u201d, \u201cshould\u201d and \u201cwill\u201d or the negative of these and similar expressions are intended to identify forward-looking statements. These forward-looking statements which are based on the Company\u2019 management\u2019s current expectations and assumptions and on information currently available to management. These forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from those implied by the forward-looking statements, including risks related to Nanobiotix\u2019s business and financial performance, which include the risk that assumptions underlying the Company\u2019s cash runway projections are not realized. Further information on the risk factors that may affect company business and financial performance is included in Nanobiotix\u2019s Annual Report on Form 20-F filed with the SEC on April 24, 2024 under \u201cItem 3.D. Risk Factors\u201d, in Nanobiotix\u2019s 2023 universal registration document filed with the AMF on April 24, 2024, in Nanobiotix\u2019 2024 semi-annual report under the caption \u201cSupplemental Risk Factor\u201d filed with the SEC on Form 6-K and with AMF on September 18 2024, and subsequent filings Nanobiotix makes with the SEC from time to time which are available on the SEC\u2019s website at www.sec.gov. The forward-looking statements included in this press release speak only as of the date of this press release, and except as required by law, Nanobiotix assumes no obligation to update these forward-looking statements publicly.<\/em>\n <\/p>\n

\n Contacts<\/strong>\n <\/p>\n\n\n\n\n\n
\n Nanobiotix<\/em>\n <\/td>\n<\/tr>\n
\n
\n
Communications Department<\/strong>
\n
\n Brandon Owens<\/em>
\n
\n VP, Communications<\/em>
\n
+1 (617) 852-4835
contact@nanobiotix.com<\/a><\/p>\n

<\/u><\/td>\n

\n Investor Relations Department<\/strong>
\n
\n Craig West<\/em>
\n
\n SVP, Investor Relations<\/em>
\n
+1 (617) 583-0211
investors@nanobiotix.com<\/a><\/td>\n<\/tr>\n
\n Media Relations<\/em>\n <\/td>\n<\/tr>\n
\n
FR \u2013 Ulysse Communication<\/strong>
Laurent Wormser
+ 33 (0)6 13 12 04 04
lwormser@ulysse-communication.com<\/a> \u2002\u2002<\/p>\n<\/td>\n		Global \u2013 LifeSci Advisors<\/strong>
Kevin Gardner
+1 (617) 283-2856
kgardner@lifesciadvisors.com<\/a><\/td>\n<\/tr>\n<\/table>\n

\u00a0<\/p>\n

\n Attachment<\/strong>\n <\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

PARIS and CAMBRIDGE, Mass., Jan. 21, 2025 (GLOBE NEWSWIRE) — NANOBIOTIX (Euronext: NANO \u2013\u2013 NASDAQ: NBTX \u2013 the \u2018\u2018Company\u2019\u2019), a late-clinical stage biotechnology company pioneering nanoparticle-based therapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced that the first patient has been dosed in the CONVERGE study, a Phase 2 randomized controlled clinical trial evaluating potential first-in-class radioenhancer JNJ-1900 (NBTXR3) for the treatment of patients with Stage 3 unresectable non-small cell lung cancer receiving standard of care chemoradiation followed by consolidation durvalumab (NCT06667908). CONVERGE is sponsored by Janssen Pharmaceutica NV, a Johnson & Johnson Company, under a global license agreement. \u201cWe believe the true value of JNJ-1900 (NBTXR3) is driven by its potential to … <\/p>\n

Continue reading “NANOBIOTIX Announces First Patient Dosed in a New Randomized Phase 2 Study Evaluating JNJ-1900 (NBTXR3) for Patients With Stage 3 Unresectable Non-Small Cell Lung Cancer”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-802373","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nNANOBIOTIX Announces First Patient Dosed in a New Randomized Phase 2 Study Evaluating JNJ-1900 (NBTXR3) for Patients With Stage 3 Unresectable Non-Small Cell Lung Cancer - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/nanobiotix-announces-first-patient-dosed-in-a-new-randomized-phase-2-study-evaluating-jnj-1900-nbtxr3-for-patients-with-stage-3-unresectable-non-small-cell-lung-cancer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"NANOBIOTIX Announces First Patient Dosed in a New Randomized Phase 2 Study Evaluating JNJ-1900 (NBTXR3) for Patients With Stage 3 Unresectable Non-Small Cell Lung Cancer - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PARIS and CAMBRIDGE, Mass., Jan. 21, 2025 (GLOBE NEWSWIRE) — NANOBIOTIX (Euronext: NANO \u2013\u2013 NASDAQ: NBTX \u2013 the \u2018\u2018Company\u2019\u2019), a late-clinical stage biotechnology company pioneering nanoparticle-based therapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced that the first patient has been dosed in the CONVERGE study, a Phase 2 randomized controlled clinical trial evaluating potential first-in-class radioenhancer JNJ-1900 (NBTXR3) for the treatment of patients with Stage 3 unresectable non-small cell lung cancer receiving standard of care chemoradiation followed by consolidation durvalumab (NCT06667908). CONVERGE is sponsored by Janssen Pharmaceutica NV, a Johnson & Johnson Company, under a global license agreement. \u201cWe believe the true value of JNJ-1900 (NBTXR3) is driven by its potential to … Continue reading "NANOBIOTIX Announces First Patient Dosed in a New Randomized Phase 2 Study Evaluating JNJ-1900 (NBTXR3) for Patients With Stage 3 Unresectable Non-Small Cell Lung Cancer"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/nanobiotix-announces-first-patient-dosed-in-a-new-randomized-phase-2-study-evaluating-jnj-1900-nbtxr3-for-patients-with-stage-3-unresectable-non-small-cell-lung-cancer\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-01-21T07:33:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMzNDY1MSM2Njk5NzM2IzEwMTExNjI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nanobiotix-announces-first-patient-dosed-in-a-new-randomized-phase-2-study-evaluating-jnj-1900-nbtxr3-for-patients-with-stage-3-unresectable-non-small-cell-lung-cancer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nanobiotix-announces-first-patient-dosed-in-a-new-randomized-phase-2-study-evaluating-jnj-1900-nbtxr3-for-patients-with-stage-3-unresectable-non-small-cell-lung-cancer\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"NANOBIOTIX Announces First Patient Dosed in a New Randomized Phase 2 Study Evaluating JNJ-1900 (NBTXR3) for Patients With Stage 3 Unresectable Non-Small Cell Lung Cancer\",\"datePublished\":\"2025-01-21T07:33:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nanobiotix-announces-first-patient-dosed-in-a-new-randomized-phase-2-study-evaluating-jnj-1900-nbtxr3-for-patients-with-stage-3-unresectable-non-small-cell-lung-cancer\\\/\"},\"wordCount\":984,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nanobiotix-announces-first-patient-dosed-in-a-new-randomized-phase-2-study-evaluating-jnj-1900-nbtxr3-for-patients-with-stage-3-unresectable-non-small-cell-lung-cancer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMzNDY1MSM2Njk5NzM2IzEwMTExNjI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nanobiotix-announces-first-patient-dosed-in-a-new-randomized-phase-2-study-evaluating-jnj-1900-nbtxr3-for-patients-with-stage-3-unresectable-non-small-cell-lung-cancer\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nanobiotix-announces-first-patient-dosed-in-a-new-randomized-phase-2-study-evaluating-jnj-1900-nbtxr3-for-patients-with-stage-3-unresectable-non-small-cell-lung-cancer\\\/\",\"name\":\"NANOBIOTIX Announces First Patient Dosed in a New Randomized Phase 2 Study Evaluating JNJ-1900 (NBTXR3) for Patients With Stage 3 Unresectable Non-Small Cell Lung Cancer - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nanobiotix-announces-first-patient-dosed-in-a-new-randomized-phase-2-study-evaluating-jnj-1900-nbtxr3-for-patients-with-stage-3-unresectable-non-small-cell-lung-cancer\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nanobiotix-announces-first-patient-dosed-in-a-new-randomized-phase-2-study-evaluating-jnj-1900-nbtxr3-for-patients-with-stage-3-unresectable-non-small-cell-lung-cancer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMzNDY1MSM2Njk5NzM2IzEwMTExNjI=\",\"datePublished\":\"2025-01-21T07:33:04+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nanobiotix-announces-first-patient-dosed-in-a-new-randomized-phase-2-study-evaluating-jnj-1900-nbtxr3-for-patients-with-stage-3-unresectable-non-small-cell-lung-cancer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nanobiotix-announces-first-patient-dosed-in-a-new-randomized-phase-2-study-evaluating-jnj-1900-nbtxr3-for-patients-with-stage-3-unresectable-non-small-cell-lung-cancer\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nanobiotix-announces-first-patient-dosed-in-a-new-randomized-phase-2-study-evaluating-jnj-1900-nbtxr3-for-patients-with-stage-3-unresectable-non-small-cell-lung-cancer\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMzNDY1MSM2Njk5NzM2IzEwMTExNjI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMzNDY1MSM2Njk5NzM2IzEwMTExNjI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nanobiotix-announces-first-patient-dosed-in-a-new-randomized-phase-2-study-evaluating-jnj-1900-nbtxr3-for-patients-with-stage-3-unresectable-non-small-cell-lung-cancer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"NANOBIOTIX Announces First Patient Dosed in a New Randomized Phase 2 Study Evaluating JNJ-1900 (NBTXR3) for Patients With Stage 3 Unresectable Non-Small Cell Lung Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"NANOBIOTIX Announces First Patient Dosed in a New Randomized Phase 2 Study Evaluating JNJ-1900 (NBTXR3) for Patients With Stage 3 Unresectable Non-Small Cell Lung Cancer - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/nanobiotix-announces-first-patient-dosed-in-a-new-randomized-phase-2-study-evaluating-jnj-1900-nbtxr3-for-patients-with-stage-3-unresectable-non-small-cell-lung-cancer\/","og_locale":"en_US","og_type":"article","og_title":"NANOBIOTIX Announces First Patient Dosed in a New Randomized Phase 2 Study Evaluating JNJ-1900 (NBTXR3) for Patients With Stage 3 Unresectable Non-Small Cell Lung Cancer - Market Newsdesk","og_description":"PARIS and CAMBRIDGE, Mass., Jan. 21, 2025 (GLOBE NEWSWIRE) — NANOBIOTIX (Euronext: NANO \u2013\u2013 NASDAQ: NBTX \u2013 the \u2018\u2018Company\u2019\u2019), a late-clinical stage biotechnology company pioneering nanoparticle-based therapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced that the first patient has been dosed in the CONVERGE study, a Phase 2 randomized controlled clinical trial evaluating potential first-in-class radioenhancer JNJ-1900 (NBTXR3) for the treatment of patients with Stage 3 unresectable non-small cell lung cancer receiving standard of care chemoradiation followed by consolidation durvalumab (NCT06667908). CONVERGE is sponsored by Janssen Pharmaceutica NV, a Johnson & Johnson Company, under a global license agreement. \u201cWe believe the true value of JNJ-1900 (NBTXR3) is driven by its potential to … Continue reading \"NANOBIOTIX Announces First Patient Dosed in a New Randomized Phase 2 Study Evaluating JNJ-1900 (NBTXR3) for Patients With Stage 3 Unresectable Non-Small Cell Lung Cancer\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/nanobiotix-announces-first-patient-dosed-in-a-new-randomized-phase-2-study-evaluating-jnj-1900-nbtxr3-for-patients-with-stage-3-unresectable-non-small-cell-lung-cancer\/","og_site_name":"Market Newsdesk","article_published_time":"2025-01-21T07:33:04+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMzNDY1MSM2Njk5NzM2IzEwMTExNjI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nanobiotix-announces-first-patient-dosed-in-a-new-randomized-phase-2-study-evaluating-jnj-1900-nbtxr3-for-patients-with-stage-3-unresectable-non-small-cell-lung-cancer\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nanobiotix-announces-first-patient-dosed-in-a-new-randomized-phase-2-study-evaluating-jnj-1900-nbtxr3-for-patients-with-stage-3-unresectable-non-small-cell-lung-cancer\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"NANOBIOTIX Announces First Patient Dosed in a New Randomized Phase 2 Study Evaluating JNJ-1900 (NBTXR3) for Patients With Stage 3 Unresectable Non-Small Cell Lung Cancer","datePublished":"2025-01-21T07:33:04+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nanobiotix-announces-first-patient-dosed-in-a-new-randomized-phase-2-study-evaluating-jnj-1900-nbtxr3-for-patients-with-stage-3-unresectable-non-small-cell-lung-cancer\/"},"wordCount":984,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nanobiotix-announces-first-patient-dosed-in-a-new-randomized-phase-2-study-evaluating-jnj-1900-nbtxr3-for-patients-with-stage-3-unresectable-non-small-cell-lung-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMzNDY1MSM2Njk5NzM2IzEwMTExNjI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nanobiotix-announces-first-patient-dosed-in-a-new-randomized-phase-2-study-evaluating-jnj-1900-nbtxr3-for-patients-with-stage-3-unresectable-non-small-cell-lung-cancer\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/nanobiotix-announces-first-patient-dosed-in-a-new-randomized-phase-2-study-evaluating-jnj-1900-nbtxr3-for-patients-with-stage-3-unresectable-non-small-cell-lung-cancer\/","name":"NANOBIOTIX Announces First Patient Dosed in a New Randomized Phase 2 Study Evaluating JNJ-1900 (NBTXR3) for Patients With Stage 3 Unresectable Non-Small Cell Lung Cancer - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nanobiotix-announces-first-patient-dosed-in-a-new-randomized-phase-2-study-evaluating-jnj-1900-nbtxr3-for-patients-with-stage-3-unresectable-non-small-cell-lung-cancer\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nanobiotix-announces-first-patient-dosed-in-a-new-randomized-phase-2-study-evaluating-jnj-1900-nbtxr3-for-patients-with-stage-3-unresectable-non-small-cell-lung-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMzNDY1MSM2Njk5NzM2IzEwMTExNjI=","datePublished":"2025-01-21T07:33:04+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nanobiotix-announces-first-patient-dosed-in-a-new-randomized-phase-2-study-evaluating-jnj-1900-nbtxr3-for-patients-with-stage-3-unresectable-non-small-cell-lung-cancer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/nanobiotix-announces-first-patient-dosed-in-a-new-randomized-phase-2-study-evaluating-jnj-1900-nbtxr3-for-patients-with-stage-3-unresectable-non-small-cell-lung-cancer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nanobiotix-announces-first-patient-dosed-in-a-new-randomized-phase-2-study-evaluating-jnj-1900-nbtxr3-for-patients-with-stage-3-unresectable-non-small-cell-lung-cancer\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMzNDY1MSM2Njk5NzM2IzEwMTExNjI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMzNDY1MSM2Njk5NzM2IzEwMTExNjI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nanobiotix-announces-first-patient-dosed-in-a-new-randomized-phase-2-study-evaluating-jnj-1900-nbtxr3-for-patients-with-stage-3-unresectable-non-small-cell-lung-cancer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"NANOBIOTIX Announces First Patient Dosed in a New Randomized Phase 2 Study Evaluating JNJ-1900 (NBTXR3) for Patients With Stage 3 Unresectable Non-Small Cell Lung Cancer"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/802373","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=802373"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/802373\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=802373"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=802373"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=802373"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}